Displaying drugs 11001 - 11025 of 12882 in total
Recombinant human type VII collagen
Investigational
Exon 55 specific phosphorothioate oligonucleotide
Investigational
Human allogeneic bone marrow derived osteoblastic cells
Investigational
Recombinant human galactocerebrosidase
Investigational
Recifercept
Investigational
Apc001PE
Investigational
Haptoglobulin (human)
Investigational
GIVI-MPC
GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.
Investigational
Human umbilical tissue derived cells
Investigational
CEQ508
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
pGM169/GL67A
Investigational
Engensis
Investigational
IR-901
Investigational
Lexanersen
Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Investigational
NeuroCell-PD
Investigational
OPC1
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
AP-101
AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.
Investigational
OT-15
Investigational
ABO-201
Investigational
NSI-566
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).
Investigational
Human ciliary neurotrophic factor, recombinant (E. coli)
Investigational
Tonabacase
Investigational
C-Alpha-stx1
Investigational
Displaying drugs 11001 - 11025 of 12882 in total